CENTRAL TRUST Co decreased its stake in Agilent Technologies Inc (NYSE:A) by 70.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,920 shares of the medical research company’s stock after selling 4,624 shares during the period. CENTRAL TRUST Co’s holdings in Agilent Technologies were worth $138,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of A. Destination Wealth Management boosted its position in Agilent Technologies by 100.0% in the first quarter. Destination Wealth Management now owns 400 shares of the medical research company’s stock valued at $32,000 after buying an additional 200 shares during the last quarter. Financial Gravity Wealth Inc. bought a new position in Agilent Technologies during the first quarter worth $52,000. Knuff & Co LLC raised its stake in Agilent Technologies by 203.3% during the first quarter. Knuff & Co LLC now owns 910 shares of the medical research company’s stock worth $73,000 after buying an additional 610 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Agilent Technologies by 36.3% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,193 shares of the medical research company’s stock valued at $96,000 after buying an additional 318 shares during the last quarter. Finally, Bremer Bank National Association bought a new stake in Agilent Technologies in the first quarter worth about $113,000.
A has been the subject of a number of research reports. Robert W. Baird reaffirmed an “outperform” rating and issued a $82.00 price objective (up previously from $79.00) on shares of Agilent Technologies in a research note on Thursday, August 15th. Zacks Investment Research lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 target price for the company. in a research note on Monday. Wolfe Research initiated coverage on shares of Agilent Technologies in a research note on Thursday, May 30th. They set a “peer perform” rating for the company. Needham & Company LLC boosted their target price on shares of Agilent Technologies to $92.00 and gave the company a “buy” rating in a research note on Monday. Finally, ValuEngine lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, July 12th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Agilent Technologies currently has a consensus rating of “Buy” and an average price target of $84.77.
Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 14th. The medical research company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Agilent Technologies had a net margin of 21.06% and a return on equity of 20.00%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 EPS. As a group, research analysts anticipate that Agilent Technologies Inc will post 3.08 earnings per share for the current year.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Further Reading: Bond
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.